(Q63570966)
Statements
Aspire II (English)
0 references
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide (English)
0 references
15 June 2017
0 references
11 April 2019
0 references
230
0 references
18 year
0 references
64 year
0 references